ResearcherAmsterdam University Medical CentersActive in the last 2 years
Etienne J. Slapak
Matched on ORCID iD 0000-0002-3228-3442; OpenAlex author ID A5003876338. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers
Papers 6
- CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.216845↗
- Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery. Co-author DOI 10.1038/s41389-024-00542-1↗
- Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer. Co-author DOI 10.3390/ijms241310704↗
- Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Co-author DOI 10.3390/pharmaceutics14020390↗
- ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Co-author DOI 10.3390/cancers13133321↗
- Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Co-author DOI 10.3390/biology9040080↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- C. Arnold Spek · 6 shared papers, 2020–2024 · strength 1.27
- Paper Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery. DOI 10.1038/s41389-024-00542-1↗
- Paper CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. DOI 10.1016/j.canlet.2024.216845↗
- Paper Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literat… DOI 10.3390/pharmaceutics14020390↗
- Maarten F. Bijlsma · 6 shared papers, 2020–2024 · strength 1.27
- Paper Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery. DOI 10.1038/s41389-024-00542-1↗
- Paper CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. DOI 10.1016/j.canlet.2024.216845↗
- Paper Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literat… DOI 10.3390/pharmaceutics14020390↗
- Cansu Tekin · 1 shared paper, 2020 · strength 0.15
- JanWillem Duitman · 1 shared paper, 2020 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.